172 related articles for article (PubMed ID: 38402561)
1. Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.
Yu Z; Xu H; Feng M; Chen L
Cancer Chemother Pharmacol; 2024 Jun; 93(6):587-593. PubMed ID: 38402561
[TBL] [Abstract][Full Text] [Related]
2. Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer.
Nihei S; Ikeda T; Aoki T; Murasato F; Yaegashi M; Asahi K; Kudo K
Cancer Chemother Pharmacol; 2023 May; 91(5):427-434. PubMed ID: 37036487
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
[TBL] [Abstract][Full Text] [Related]
4. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
Iwasa S; Nakajima TE; Nagashima K; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2013 Jan; 33(1):309-16. PubMed ID: 23267162
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
7. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status.
Yamada Y; Yoshimatsu K; Yokomizo H; Okayama S; Satake M; Ida A; Maeda H; Shiozawa S
J Nippon Med Sch; 2021 Nov; 88(5):496-499. PubMed ID: 32999176
[TBL] [Abstract][Full Text] [Related]
9. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
10. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
Willems E; Gerne L; George C; D'Hondt M
Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
[TBL] [Abstract][Full Text] [Related]
12. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
[TBL] [Abstract][Full Text] [Related]
13. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.
Tahover E; Hubert A; Temper M; Salah A; Peretz T; Hamburger T; Uziely B
Target Oncol; 2015 Mar; 10(1):55-63. PubMed ID: 24599713
[TBL] [Abstract][Full Text] [Related]
14. Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies.
Lee CS; Alwan LM; Sun X; McLean KA; Urban RR
J Oncol Pharm Pract; 2016 Dec; 22(6):771-776. PubMed ID: 26447100
[TBL] [Abstract][Full Text] [Related]
15. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
[TBL] [Abstract][Full Text] [Related]
17. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
[TBL] [Abstract][Full Text] [Related]
18. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
19. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf S; Bertelli G; Ograbek A; Field P; Tran I
Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
